RecruitingPhase 3NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Sponsor: Merck Sharp & Dohme LLC
Irvine, CA · Los Angeles, CA · Orange, CA · +60 more sites